Abstract Number: 1254 • 2015 ACR/ARHP Annual Meeting
Deciphering the Immunome of Clinically Effective Immune Tolerization in Rheumatoid Arthritis
Background/Purpose: We have previously described (Nature Medicine, PNAS, A&R, Nature Rheum, Lancet) how oral treatment with the pro-inflammatory, heat shock protein-derived dnaJP1 peptide induces detectable…Abstract Number: 1309 • 2015 ACR/ARHP Annual Meeting
Defining an Acceptable Level of MRI Inflammation in Rheumatoid Arthritis
Background/Purpose: Imaging-detected inflammation persists in many rheumatoid arthritis (RA) patients despite therapy. We used data from two clinical trials of golimumab to determine thresholds for…Abstract Number: 1661 • 2015 ACR/ARHP Annual Meeting
Translational Data and Phase 1 Study Results of a New Monoclonal Antibody Targeting Toll like Receptor 4 (TLR4) Developed for Rheumatoid Arthritis (RA) Treatment with a Potential for Personalized Medicine
Background/Purpose: Innate immunity is implicated in RA pathogenesis and is likely mediated via TLR pathways, with anti-citrullinated protein antibodies (ACPA) serving as key triggers. NI-0101…Abstract Number: 1664 • 2015 ACR/ARHP Annual Meeting
Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.
Background/Purpose: Tocilizumab (TCZ) represents an efficacious alternative for patients with rheumatoid arthritis (RA) with an inadequate clinical response to biological or non-biological disease-modifying anrirheumatic drugs…Abstract Number: 2111 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) to treat gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular UA transporter, and…Abstract Number: 2302 • 2015 ACR/ARHP Annual Meeting
The Impact of Prior Fibromyalgia Treatment on the Response to Pregabalin in Fibromyalgia Clinical Trials
Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder for which Lyrica is an approved treatment. Antidepressants, gabapentin, muscle relaxants, and opioids are frequently used…Abstract Number: 2440 • 2015 ACR/ARHP Annual Meeting
Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis
Background/Purpose: To define distinct disease course groups among children with Juvenile Idiopathic Arthritis (JIA) based on observed changes in quality of life, pain, medication requirements,…Abstract Number: 2754 • 2015 ACR/ARHP Annual Meeting
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of BI 655064, an Antagonistic Anti-CD40 Antibody Following Single-Dose Administration in Chinese and Japanese Healthy Volunteers
Background/Purpose: The CD40-CD40L pathway may play a major role in autoimmune disorders like rheumatoid arthritis or SLE. Blocking this pathway may be a promising new…Abstract Number: 3145 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Modified-Release Prednisone in Patients with Polymyalgia Rheumatica: Results of a Multicenter, Randomized, Active-Controlled Phase 3 Study
Background/Purpose: Polymyalgia rheumatica (PMR) is characterized by persisting proximal pain and morning stiffness of the neck, shoulder and hip girdles of 2 weeks' duration, an…Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression
Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…Abstract Number: 259 • 2014 ACR/ARHP Annual Meeting
Development of Pediatric Item Banks to Measure Pain Behavior in the Patient Reported Outcomes Measurement Information System
Background/Purpose The NIH Patient Reported Outcomes Measurement Information System (PROMIS) has created publicly available patient reported outcomes measures in several domains of physical, social and…Abstract Number: L15 • 2014 ACR/ARHP Annual Meeting
Remission Induction By Etanercept in Enthesitis Related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy)
Background/Purpose: Enthesitis related arthritis (ERA) is a Juvenile Idiopathic Arthritis category, clinically related to the syndrome of undifferentiated spondyloarthropathy in adults. This study is intended…Abstract Number: 2230 • 2014 ACR/ARHP Annual Meeting
Treatment of Symptomatic Knee Osteoarthritis with Oral Salmon Calcitonin: Results from Two Phase 3 Randomized Clinical Trials
Background/Purpose: To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a…Abstract Number: 1553 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Background/Purpose: Early non-response to biologic therapy has been shown to be associated with a low probability of long-term response in rheumatoid arthritis1 and psoriasis2. However,…Abstract Number: 1505 • 2014 ACR/ARHP Annual Meeting
The Biosimilar Landscape: A Systematic Review of Its Current Status
Background/Purpose In the last 5 years, the number of biosimilars in development for the treatment of immunologic diseases has increased as innovator etanercept (ETA), infliximab (IFX), adalimumab…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- Next Page »